Heart failure & cardiomyopathiesCohort study
Outpatient Worsening of Heart Failure and Mortality in Transthyretin Amyloid Cardiomyopathy
- Retrospective cohort study
- single-centre
Authors' conclusion
In contemporary patients with ATTR-CM treated with tafamidis, WHF requiring ODI is prognostic of subsequent mortality and is a clinical marker of disease progression.
Study context
- Population
- ATTR-CM patients highly treated with tafamidis, Columbia University Irving Medical Center
- Participants
- 145 / 35 / 152
- Exposure
- Worsening heart failure (WHF) events vs no WHF event
- Outpatient diuretic intensification (ODI)n = 145
- Heart failure (HF) hospitalizationn = 35
- No WHF eventsn = 152reference
- Outcome
- All-cause mortality after a WHF event:
- Hospitalization
- ODI
Main finding
As reported in the abstract
All-cause mortality
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Outpatient Worsening of Heart Failure and Mortality in Transthyretin Amyloid Cardiomyopathy. Eur J Heart Fail. Published 5 December 2024. doi:10.1002/ejhf.3540
Summarised from the published abstract; every number is checked against it